## GF/B45/EDP18 Approval of the Secretariat's Recommendation on Funding from the COVID-19 Response Mechanism (Central African Republic)

## Approved on 30 September 2021

The Board:

- 1. Notes its decision in GF/B44/EDP18, which requires the Secretariat to recommend to the Board, for its approval, any COVID-19 Response Mechanism ("C19RM") awards exceeding US\$35 million, as measured in aggregate by country (not including any funding awarded for COVID-19 commodities through fast-track investments or C19RM funding awarded in 2020);
- 2. Approves the funding recommended for each country, as listed in Table 1 of GF/B44/ER17; and
- 3. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country among its constituent grants in accordance with the previously approved principles under GF/B44/EDP18.

This decision does not raise new, material budgetary implications for operating expenses.

## Table 1: Secretariat's Recommendation on Funding from C19RM<sup>1</sup>

Please note that each country name is linked to the extranet site where relevant supporting documents are available for review.

Country / Multicountry	Grant name	Currency	C19RM 2020 carry-over amount <sup>2</sup>	Previously approved C19RM 2021 award <sup>3</sup>	C19RM 2021 recommended amount for Board approval	Total C19RM 2021 funding	% of 2020- 2022 allocation	Total C19RM 2021 funding plus C19RM 2020 carry-over	C19RM Unfunded Demand
<u>Central</u> <u>African</u> <u>Republic</u>	CAF-C-CRF	EUR	312,483	0	27,232,403	32,992,851	27.09%	35,119,135	0
	CAF-M-WVI	EUR	1,813,801	0	5,760,448				

<sup>&</sup>lt;sup>1</sup> The C19RM Investment Committee recommends C19RM Full Funding Requests awards of more than US\$35 million to the Global Fund Board for approval. This amount, measured in aggregate per country, does not include any funding awarded through the C19RM Fast-track process or through C19RM in 2020. The C19RM Investment Committee may also recommend awards under US\$35 million to the Global Fund Board for approval where it determines that the non-health product components of an award are of a nature and scale which raise significant concerns about risk and complexity.

<sup>&</sup>lt;sup>2</sup> Estimated funds remaining from C19RM 2020 awards previously approved by the C19RM Investment Committee and carried over to this new award.

<sup>&</sup>lt;sup>3</sup> This includes Secretariat approved Fast-track and Full Funding awards, as well as awards previously approved by the Board.